Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00110786
Status:
COMPLETED
Last Update Posted:
2010-06-17
First Post:
2005-05-13
Brief Title:
Investigation of Efficacy and Safety of Ragweed MATAMPL Pollinex-R and Placebo in Patients With Ragweed Allergy
Sponsor:
Allergy Therapeutics
Organization:
Allergy Therapeutics
Study Overview
Official Title:
A Double Blind Study to Investigate the Clinical Efficacy and Safety of Ragweed MATAMPL Allergy Therapeutics Pollinex-R Allergy Therapeutics and Placebo in Patients With Seasonal Allergic Rhinitis With Ragweed Allergy in an Environmental Exposure Chamber EEC Model With Follow-Up During a Natural Ragweed Pollen Season
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Ragweed MATAMPL has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to ragweed pollen hay fever This novel formulation is designed to provide a vaccine that will be efficacious with only four escalating dose injections administered before the start of the pollen season
In this study the safety and efficacy of Ragweed MATAMPL will be assessed by exposing allergic subjects to Ragweed pollen in an environmental exposure chamber EEC Patient symptomatic response to pollen and patient quality of life in the EEC will be determined
In this study the safety and efficacy of Ragweed MATAMPL will be assessed by exposing allergic subjects to Ragweed pollen in an environmental exposure chamber EEC Patient symptomatic response to pollen and patient quality of life in the EEC will be determined
Detailed Description:
Allergic rhinitis is a nasal inflammatory disorder initiated by an immunoglobulin-E IgE mediated hypersensitivity to allergens This condition is characterized by sneezing rhinorrhea nasal itching and congestion When a patient is exposed to an allergen to which they are sensitive the allergen cross-links with the Ig E antibody which is bound to the surface of tissue mast cells This cross-linking then triggers the release of proinflammatory substances such as histamine and eicosanoids and is known as the early response In a skin prick test this reaction produces a wheal-and-flare response Normally systemic exposure to an allergen also leads to the more prolonged late reaction in which eosinophils basophils and activated T cells are recruited to the site of exposure The recruited T cells also secrete inflammatory cytokines such as interleukin-4 IL-4 and IL-5 typically associated with helper T cells type 2 TH2 which further propagate the inflammatory cascade Typically the early response occurs within 15 to 30 minutes but as quickly as a few seconds and usually resolves within 1 to 3 hours and the late response occurs within 6 to 12 hours and resolves in 24 hours
Allergic vaccination AV also referred to as immunotherapy or allergen-specific immunotherapy SIT is a curative approach that is available for allergic diseases which directly treats the underlying disease AV is the practice of administering gradually increasing quantities of an allergen extract to an allergic patient to ameliorate the symptoms associated with the subsequent exposure to the causative allergen AV is believed to exert its beneficial effects on the immune system at least in part by modifying the T-lymphocyte response to subsequent natural allergen exposure AV has been shown to inhibit both early and late responses to allergen exposure AV acts on T cells to modify peripheral and mucosal TH2 responses to allergen in favor of helper T cell type 1 TH1 responses One of the hallmarks of successful AV is the redressing of a healthy TH1TH2-balance
Although efficacious immunotherapy is generally considered a long-term disease modifying measure that requires months to years of treatment entails multiple injection regimens and involves some risk for adverse immune reactions
Recent improvements such as optimal dosing allergen modification to reduce allergenicity while maintaining immunogenicity adjuvant adsorption to control release and adjuvant activity to assist immunomodulatory action are being explored to reduce the risk of anaphylaxis and decrease the commitment to multiple injections
A novel allergy vaccine Ragweed MATAMPL has been developed for the prevention or relief of allergic symptoms caused by a variety of pollens Ragweed MATAMPL which contains the allergens of ragweed chemically modified by glutaraldehyde adsorbed onto L-tyrosine with the addition of the adjuvant monophosphoryl lipid A MPL is being evaluated for the specific treatment of ragweed seasonally induced allergic rhinitis Ragweed MATAMPL is intended for use as a pre-seasonal therapeutic allergy vaccine in patients with proven seasonal allergic rhinitis and conjunctivitis due to IgE mediated allergy to ragweed This novel vaccine formulation is designed to provide a vaccine that will be efficacious with only four escalating dose injections in contrast to the longer schedules currently in use
This placebo-controlled clinical trial is designed to evaluate the safety and efficacy of Ragweed MATAMPL as determined by patient symptomatic response to pollen and patient quality of life in an environmental exposure chamber EEC that reproduces the clinical setting The development of the EEC which delivers a controlled pollen challenge over time and allows evaluation of a patients response at any time point throughout the challenge process provides the opportunity to examine various aspects of efficacy of anti-allergic treatments within a single center at various times of the year The EEC affords a more controlled environment than natural pollen exposure in which variables such as unpredictable pollen levels varying weather conditions during the study period and varying levels of pollen exposure within the patient population are eliminated Furthermore the question of patient compliance is largely eliminated because the patients are scrutinized closely while they are recording symptoms In addition an EEC study is an acceptable study model for determining the dose response for an allergic rhinitis drug as outlined in the draft US Food and Drug Administration FDA guidelines Allergic Rhinitis Clinical Development Programs for Drug Products April 2000
Allergic vaccination AV also referred to as immunotherapy or allergen-specific immunotherapy SIT is a curative approach that is available for allergic diseases which directly treats the underlying disease AV is the practice of administering gradually increasing quantities of an allergen extract to an allergic patient to ameliorate the symptoms associated with the subsequent exposure to the causative allergen AV is believed to exert its beneficial effects on the immune system at least in part by modifying the T-lymphocyte response to subsequent natural allergen exposure AV has been shown to inhibit both early and late responses to allergen exposure AV acts on T cells to modify peripheral and mucosal TH2 responses to allergen in favor of helper T cell type 1 TH1 responses One of the hallmarks of successful AV is the redressing of a healthy TH1TH2-balance
Although efficacious immunotherapy is generally considered a long-term disease modifying measure that requires months to years of treatment entails multiple injection regimens and involves some risk for adverse immune reactions
Recent improvements such as optimal dosing allergen modification to reduce allergenicity while maintaining immunogenicity adjuvant adsorption to control release and adjuvant activity to assist immunomodulatory action are being explored to reduce the risk of anaphylaxis and decrease the commitment to multiple injections
A novel allergy vaccine Ragweed MATAMPL has been developed for the prevention or relief of allergic symptoms caused by a variety of pollens Ragweed MATAMPL which contains the allergens of ragweed chemically modified by glutaraldehyde adsorbed onto L-tyrosine with the addition of the adjuvant monophosphoryl lipid A MPL is being evaluated for the specific treatment of ragweed seasonally induced allergic rhinitis Ragweed MATAMPL is intended for use as a pre-seasonal therapeutic allergy vaccine in patients with proven seasonal allergic rhinitis and conjunctivitis due to IgE mediated allergy to ragweed This novel vaccine formulation is designed to provide a vaccine that will be efficacious with only four escalating dose injections in contrast to the longer schedules currently in use
This placebo-controlled clinical trial is designed to evaluate the safety and efficacy of Ragweed MATAMPL as determined by patient symptomatic response to pollen and patient quality of life in an environmental exposure chamber EEC that reproduces the clinical setting The development of the EEC which delivers a controlled pollen challenge over time and allows evaluation of a patients response at any time point throughout the challenge process provides the opportunity to examine various aspects of efficacy of anti-allergic treatments within a single center at various times of the year The EEC affords a more controlled environment than natural pollen exposure in which variables such as unpredictable pollen levels varying weather conditions during the study period and varying levels of pollen exposure within the patient population are eliminated Furthermore the question of patient compliance is largely eliminated because the patients are scrutinized closely while they are recording symptoms In addition an EEC study is an acceptable study model for determining the dose response for an allergic rhinitis drug as outlined in the draft US Food and Drug Administration FDA guidelines Allergic Rhinitis Clinical Development Programs for Drug Products April 2000
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| P2DP05001 | None | None | None |